Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLCTony Mok, Gilberto Lopes, Yi‐Long Wu et al.|Annals of Oncology|2019Cited by 39
FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLCByoung Chul Cho, Tony Mok, Yi‐Long Wu et al.|Journal of Thoracic Oncology|2021Cited by 28
Quantitative Evaluation of Renal Excretion on the Dynamic DTP A Renal ScanKazuo Kubota, William Pollack, Harold Atkins et al.|Clinical Nuclear Medicine|1989Cited by 14